Snap Bio's unique drug discovery platform starts with extremely potent inhibitors that have been evolved in Nature over millions of years. Rather than relying solely on conventional medicinal chemistry to modify these privileged scaffolds, Snap Bio employs its breakthrough synthetic biology platform, including proprietary cell-free-biosynthesis (CFB) technology, along with structure-based drug design, to develop novel new chemical entities (NCEs). This unique marriage of technologies is enabling structural modification of these modular scaffolds in ways that previously were not possible, thus allowing us to rapidly optimize selectivity, solubility, metabolic stability, and other properties important for clinical success.
Our innovative approach has enabled us to develop a new class of bispecific inhibitors that can simultaneously and selectively inhibit multiple targets. Disease is often caused by more than one dysfunctional enzyme or pathway and the ability to design molecules that exhibit precision polypharmacology can afford significant benefits, such as higher efficacy, fewer side effects, and reduced drug resistance. In addition, bispecific inhibitors can target multiple disease pathways without pharmacokinetic disparity, leading to easier, faster, cheaper, and lower risk in clinical trials relative to drug combination therapies,” Snap Bio is advancing its bispecific inhibitor platform and is focused on developing new molecules that simultaneously inhibit kinases and other targets involved in cancer.